Zhang X J, Wu Z W, Zhang Y H, Li M J, Zhou H S, Han B H, Hao Z Y, Chu J, Gao Z, Ma J C, Zhao Y L
Zhengding County Center for Disease Control and Prevention，Shijiazhuang 050800, China.
Hebei Province Center for Disease Control and Prevention, Shijiazhuang 050021, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2020 Sep 6;54(9):942-946. doi: 10.3760/cma.j.cn112150-20200509-00710.
Aanalysis the effect of booster one dose of hepatitis B vaccine after 21-32 years of primary immunization in Zhengding Country of Hebei Province. A total of 322 participants who were born between 1986 and 1996, received a full course of primary vaccination with plasma-derived hepatitis B vaccine (HepB), had no experience with booster vaccination, were HBsAg, anti-HBcnegative, had anti-HBs<10 mIU/ml, completed the booster and had laboratory results were enrolled between August 2017 to February 2018. A simple random method was uesd to randomly assigned 322 subjects to two groups, receiving a booster dose of HepB derived from either Saccharomyces cerevisiae ［HepB (SC), (151 cases)］ or Chinese hamster ovary-derived HepB ［HepB (CHO), (171 cases)］, the dose was 20 μg. Blood samples were collected 30 days after boosting and quantitatively tested for the geometric mean concentration (GMC) of anti-HBs to assess immunological effect. The related influencing factors of GMC and seroconversion rates of anti-HBs were analyzed by multiple linear regression and multivariate logistic regression models. The 266 subjects (82.61%) had anti-HBs≥ 10 mIU/ml, and GMC was (131.63±12.94) mIU/ml.The seroconversion rates of anti-HBs in the anti-HBs<2.5 mIU/ml group and 2.5-10 mIU/ml group were 74.54% (161 cases) and 99.06% (105 cases), respectively (<0.001).The seroconversion rates of anti-HBs after one dose of HepB (CHO) was higher than that of one dose of HepB (SC), the seroconversion rates were 87.13% (149 cases) and 77.48% (117 cases), respectively (=0.023). Participants boostered with HepB (CHO) was the factor influencing the effect of strengthening immunization compared with boostered with HepB (SC), and (95%) was 1.91 (1.02-3.56) (=0.042).Compared with anti-HBs<2.5 mIU/ml, prebooster anti-HBs was between 2.5 mIU/ml and 10 mIU/ml was the related factor of seroconversion rates of anti-HBs after booster immunization, and (95%) was 36.15 (4.91-266.02) (<0.001). Participants boostered withone dose of HepB had a good immune response. Pre-booster anti-HBs concentration and a variety of vaccine were related factors of immune response.
分析河北省正定县初次免疫21 - 32年后追加一剂乙肝疫苗的效果。选取1986年至1996年出生、接受过全程血源性乙肝疫苗（HepB）基础免疫、无追加免疫史、HBsAg和抗 - HBc阴性、抗 - HBs<10 mIU/ml、完成追加免疫且有实验室检测结果的322名参与者，于2017年8月至2018年2月纳入研究。采用简单随机方法将322名受试者随机分为两组，分别接种20μg来源于酿酒酵母的乙肝疫苗［HepB（SC），151例］或中国仓鼠卵巢细胞表达的乙肝疫苗［HepB（CHO），171例］。追加免疫30天后采集血样，定量检测抗 - HBs的几何平均浓度（GMC）以评估免疫效果。通过多元线性回归和多因素logistic回归模型分析GMC及抗 - HBs血清转化率的相关影响因素。266名受试者（82.61%）抗 - HBs≥10 mIU/ml，GMC为（131.63±12.94）mIU/ml。抗 - HBs<2.5 mIU/ml组和2.5 - 10 mIU/ml组抗 - HBs血清转化率分别为74.54%（161例）和99.06%（105例）（<0.001）。一剂HepB（CHO）后抗 - HBs血清转化率高于一剂HepB（SC），血清转化率分别为87.13%（149例）和77.48%（117例）（=（此处原文有误，推测应为P）0.023）。与接种HepB（SC）相比，接种HepB（CHO）是影响强化免疫效果的因素，比值比（95%CI）为1.91（1.02 - 3.56）（=（此处原文有误，推测应为P）0.042）。与抗 - HBs<2.5 mIU/ml相比，追加免疫前抗 - HBs在2.5 mIU/ml至10 mIU/ml之间是追加免疫后抗 - HBs血清转化率的相关因素，比值比（95%CI）为36.15（4.91 - 到此处原文结束，推测应为266.02）（<0.001）。一剂HepB追加免疫的参与者有良好的免疫反应。追加免疫前抗 - HBs浓度及多种疫苗是免疫反应的相关因素。
